The HAT1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma epithelial cell line. This product disrupts the HAT1 gene, encoding histone acetyltransferase 1, providing a loss-of-function model to investigate its roles in chromatin biology and cancer. The heterogeneous population offers a flexible tool for studying gene function without clonal selection, enabling population-level analyses of HAT1-dependent processes.
The A-549 cell line was originally established from a lung carcinoma of a 58-year-old Caucasian male and displays epithelial morphology. It serves as a widely used in vitro model of lung adenocarcinoma, recapitulating key features of alveolar epithelial cells. This host background is particularly relevant for studying oncogenic signaling, DNA damage responses, and chromatin remodeling in the context of non-small cell lung cancer, making it an ideal platform for interrogating the epigenetic functions of HAT1.
HAT1 is a type B histone acetyltransferase that specifically acetylates newly synthesized histone H4 on lysine residues K5 and K12. This modification is critical for chromatin assembly and DNA replication-coupled nucleosome deposition. The enzyme functions in a multi-chaperone complex with NASP, ASF1a/b, and the CAF-1 chromatin assembly factor, facilitating the transfer of H3?H4 tetramers onto nascent DNA. HAT1 activity is regulated by cell cycle signals and DNA damage pathways, positioning it as a key mediator of genome maintenance. Downstream, H4K5/K12 acetylation by HAT1 promotes chromatin maturation and influences DNA double-strand break repair. Disruption of HAT1 leads to altered histone modification patterns, impaired chromatin structure, and genomic instability.
In A-549 cells, HAT1 knockout provides a physiologically relevant system to dissect the interplay between histone acetylation and lung adenocarcinoma progression. Since HAT1 depletion compromises chromatin integrity and DNA repair, this model enables investigation of sensitization to genotoxic agents and the role of epigenetic dysregulation in cancer. It allows researchers to directly assess how loss of a key histone-modifying enzyme affects proliferation, cell cycle checkpoints, and drug sensitivity in an epithelial tumor context, linking basic chromatin biology to translational oncology.
Typical applications include monitoring histone H4 acetylation dynamics via western blotting or ChIP-qPCR, assessing DNA damage accumulation with comet assays, and evaluating chromatin organization through immunofluorescence. The polyclonal population is also suitable for inhibitor screening campaigns and cell cycle analysis by flow cytometry. Researchers can use colony formation assays to test therapeutic responses in the absence of HAT1. For additional details, please contact Ascent Research.
